AML-961: CDK4/6 Inhibitor Use and Risk of Therapy-Related Myeloid Neoplasms Following Chemotherapy for HR+/HER2–Breast Cancer: A Landmark Competing Risks Analysis
Year: 2026
Type: conference-abstract
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: CDK4/6 inhibitors, therapy-related myeloid neoplasms, hormone receptor-positive HER2-negative breast cancer, chemotherapy, myelodysplastic syndrome, acute myeloid leukemia, leukemogenesis, hematopoietic stem cell quiescence, competing risks, landmark analysis, immortal time bias, anthracycline chemotherapy
Open Access status: closed
OpenAlex ID: W7204689535
